Access and Evidence
Keeping it real: How data is driving healthcare reform in China
China’s healthcare market is ripe for those capable of helping it capture the vast potential of real-world data
More Articles
Medical
On the journey from pill to platform
For AstraZeneca’s Alex Bedenkov, investing more in post-pandemic medical capabilities is just the start of a far more profound organisation-wide transformation
Patients and Medical
Optimizing patient Engagement in Trials
The importance of involving the patient at all stages of trials post-pandemic has never been clearer
Patients and Medical
Fixing the broken patient search experience
There’s opportunity as well as danger in the billion healthcare searches made every day. Why isn’t pharma tuning in?
Access and Evidence
Including the caregiver in access submissions
Partnering with caregivers can help build a more powerful case for re-imbursement if pharma can gather the right evidence
Medical
From insight to action in medical affairs
Physicians’ increasingly digital-first consumption of disease state education offers pharma a way to understand their needs more deeply and so find better ways to serve them
Clinical
How collaboration will strengthen the future of cell and gene therapies
As clinical science continues to deliver on the promise of CGT, how can the industry make them available and affordable at scale?
Multichannel
How US pharma is charting a new course in a changed world
Post-Trump and post pandemic, pharma in the US is eyeing emerging commercial and clinical opportunities, but must reckon with potential storms ahead
Medical
Redefining the role of the MSL in a changed world
MSLs will need to respond to the growing demands being placed on them in the new normal by adopting new approaches, capabilities and skill sets
Commercial
Accelerating commercial success in CAGT
To build on the successes thus far in cell and gene therapy, pharma must foster further payer, physician and patient buy-in